---
figid: PMC9170863__12672_2022_510_Fig4_HTML
figtitle: TEMTing target? Clinical and experimental evidence for epithelial-mesenchymal
  transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic
  review)
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC9170863
filename: 12672_2022_510_Fig4_HTML.jpg
figlink: /pmc/articles/PMC9170863/figure/Fig4/
number: F4
caption: Synthesis of EMT signalling in cSCC based on clinical and experimental studies
  evaluated in this review (Supplementary Table 1 and 2). The signalling investigated
  by cell line-based studies was merged in this EMT pathway map under the assumption
  of transferability between the different aetiologies and models. Multiple changes
  can induce EMT in cSCC. Hormonal, cytokine, growth factor, ECM signalling all contribute
  cooperatively to the extent and nature of the EMT programme. Central signalling
  hubs such as Akt, MKKs or NFκB are attractive drug targets that could be used to
  attenuate EMT in cSCC []
papertitle: A tEMTing target? Clinical and experimental evidence for epithelial-mesenchymal
  transition in the progression of cutaneous squamous cell carcinoma (a scoping systematic
  review).
reftext: Benjamin Genenger, et al. Discov Oncol. 2022 Dec;13:42.
year: '2022'
doi: 10.1007/s12672-022-00510-4
journal_title: Discover. Oncology
journal_nlm_ta: Discov Oncol
publisher_name: Springer US
keywords: Epithelial-mesenchymal transition | Cutaneous squamous cell carcinoma |
  Metastasis | Targeted therapy | Urokinase plasminogen activator system | Systematic
  review | UV-induced
automl_pathway: 0.8401725
figid_alias: PMC9170863__F4
figtype: Figure
redirect_from: /figures/PMC9170863__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9170863__12672_2022_510_Fig4_HTML.html
  '@type': Dataset
  description: Synthesis of EMT signalling in cSCC based on clinical and experimental
    studies evaluated in this review (Supplementary Table 1 and 2). The signalling
    investigated by cell line-based studies was merged in this EMT pathway map under
    the assumption of transferability between the different aetiologies and models.
    Multiple changes can induce EMT in cSCC. Hormonal, cytokine, growth factor, ECM
    signalling all contribute cooperatively to the extent and nature of the EMT programme.
    Central signalling hubs such as Akt, MKKs or NFκB are attractive drug targets
    that could be used to attenuate EMT in cSCC []
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CDH1
  - FZR1
  - HOTAIR
  - RIT2
  - PRAF2
  - CTNNB1
  - GAL
  - GALP
  - SNAI2
  - SNAI1
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - BTG3
  - PADI2
  - GTF2H1
  - SQSTM1
  - KHDRBS1
  - NUP62
  - DCTN4
  - MIR22
  - DKK1
  - TWIST1
  - AXL
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - ANXA6
  - DDX5
  - POLD3
  - GATAD2B
  - APLN
  - PIK3R1
  - PIK3R2
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - IL6
  - TRAM1
  - NCOA3
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - MIR181A1
  - PDK1
  - PDPK1
  - REG3A
  - ASAP2
  - MRPS30
  - PAPOLA
  - PDAP1
  - TUSC2
  - ASAP1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - RPE65
  - UVRAG
  - TP63
  - CKAP4
  - PTGS2
  - DDC
  - MIR206
  - EGFR
  - NANOG
  - MAPK3
  - MAPK1
  - ITK
  - SLC22A3
  - LRPAP1
  - MAP2K1
  - MKKS
  - MAPK8
  - MAPK9
  - MAPK10
  - BRF1
  - CRK
  - MAPK14
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - NOX1
  - ACP1
  - ROCK1
  - MROCKI
  - SMAD3
  - SMAD1
  - SMAD4
  - SMAD5
  - SMAD6
  - SMAD7
  - SMAD9
  - SMAD2
  - MARK2
  - F2R
  - PWAR1
  - SOX2
  - KLF4
  - TWF2
  - STAT3
  - FN1
---
